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Introduction: Sclerostin is a key negative regulator of bone formation. Recently, sclerostin was identified for the first time in human aortas at the 
protein level. We hypothesized that sclerostin may also play a potential role in the development of aortic valve calcification (AVC).
Methods: A cross-sectional study in 149 patients (mean age 76 ± 8 years) with echocardiographically proven AVC was performed. In all patients 
serum sclerostin levels were measured by ELISA (Tecomedical, Bünde, Germany) and compared to values obtained from a healthy control population 
(n=57, age 48 ± 20 years). For quantification of AVC and CAC all patients of the study cohort underwent non contrast-enhanced DSCT (Definition, 
Siemens, Germany). Immunohistochemistry (IHC) staining for sclerostin and mRNA sclerostin expression was analyzed in 5 calcified aortic valves and 
5 non-calcified control valves obtained from 5 age matched control subjects.
Results: Patients with AVC showed significantly higher sclerostin serum levels as compared to healthy controls (0.91 ± 0.48 vs. 0.58 ± 0.26 ng/mL, 
p<0.001). A significant correlation between sclerostin serum levels and Agatston AVC scores assessed by DSCT was observed (r= 0.50, p<0.001) in 
the study cohort. IHC revealed a positive sclerostin staining in three calcified valves compared to negative staining for sclerostin in all control valves 
was observed. Quantitative realtime PCR confirmed the increased sclerostin expression on mRNA level with a significant upregulation of sclerostin 
mRNA (fold change 108±53, p = 0.002) expression was shown in calcified aortic valves compared to non-calcified control valves.
Conclusions: Patients with AVC showed increased sclerostin serum levels compared to a healthy reference population and revealed that the 
severity of AVC may be linked to increased sclerostin serum levels. IHC and PCR data demonstrated an association between the presence of AVC and 
aortic valve sclerostin production and deposition indicating a role of sclerostin in the valvular calcification process.
